Key:
C = CALGB
E = ECOG
N = NSABP
P = Pharmacy
R = RTOG
S = SWOG
CTSU= NCI Cancer Trials Support Unit
V = Vermont Cancer Center
Updated 5/27/09
Anemia:
CTSU E2905
- Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and
in Combination with Epoetin Alfa (Procrit®) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Breast:
N B37
- A Randomized trial of adjuvant chemotherapy for radically resected loco-regional relapse of breast cancer
N B40
- A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable & Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens
N B41
- A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable & Operable HER2+ Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab & to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
N B42
- Trial to determine the efficacy of 5 Yars of Letrozole compared to placebo in patients completing 5 years of hormonal Tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor positive breast cancer
N B43
- A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
N B44
- A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients
with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy
PlusTrastuzumab Plus Bevacizumab
C 40502
- A randomized phase III trial of weekly paclitaxel compared to weekly nanoparticle albumin bound nab-paclitaxel or ixabepilone combined with bevacizumab as 1st line therapy for locally recurrent or metastatic breast cancer
CTSU-E1105
- A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-expressing Metastatic Breast Cancer
CTSU S0307
- Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer
CTSU PACCT-1
- Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial
CTSU N0733
- Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 in Patients with HER2 Positive Breast Cancer Previously Treated with Trastuzumab and an Anthracycline and/or a Taxane
CTSU S0500
- A randomized phase III trial to test the strategy of changing therapy vs. maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell levels at first follow-up assessment
V 0308
- Clinical and Molecular Markers of Breast Cancer Risk – Blood and Tissue Collection
V 0407
- Statins and Breast Cancer Biomarkers: Evaluation of Breast Density and Serum Biomarkers in Response to Statin Administration
Colorectal:
N C10
- A Phase II Trial of 5-Fluorouracil, Leucovorin, & Oxaliplatin (mFOLFOX6) Chemotherapy Plus Bevacizumab for Patients with Unresectable Stage IV Colon Cancer & a Synchronous Asymptomatic Primary Tumor
N R-04
- A trial comparing pre-op RT and Capecitabine with pre-op RT and continuous IV infusion (CVI) of 5FU in the treatment of patients with operable rectal cancer
Gastric/Gastroestroesophageal:
CTSU-RTOG-0436
- Phase III Trial evaluating the addition of Cetuximab to Paclitaxel, Cisplatin and RT for Patients with esophageal cancer who are treated without surgery
GIST:
CTSU-S0502
- A phase III randomized trial of Imatinib, with or without Bevacizumab in patients with metastatic or unresectable gastrointestinal stromal tumors
Head & Neck:
CTSU E-1305
- A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab In Patients with Recurrent Or Metastatic Head and Neck Cancer
Leukemia:
C 8461
- Mandatory Companion Study for Other Protocols; Cytogenetics
C 9665
- Mandatory Companion Study for Other Protocols; Tissue Banking
C 10602
- A Randomized Phase II Trial of Azacitidine with or without the Histone Deacetylase Inhibitor MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with Multilineage Dysplasia
C 29801
- Mandatory Companion Study for Other Protocols; Molecular Maonitoring in CML
Lung: SCLC Limited:
C 30610
- Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide
Lung: SCLC Extensive:
C 30504
- Combination Cisplatin, Etoposide and Sunitinib for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/II Study
Lung: SCLC Relapsed:
Lung: NSCLC Limited:
CTSU-E1505
- A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC)
Lung: NSCLC Stage III:
C 30605
- A Phase II Study of Induction Chemotherapy followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non-small Cell Lung Cancer
***Temp. Suspension***
Lung: NSCLC Advanced:
C 30704
- A randomized phase II study to assess the efficacy of Premetrexed or Sunitinib or Pemetrexed plus Sunitinib in 2nd line treatment of advanced NSCLC
C 30607
- Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer
CTSU-N0723
- MARVEL: Marker Validation of Erlotinib in Lung Cancer - A Phase III Biomarker Validation study of Second-line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) randomized to Pemetrexed Versus Erlotinib
Lymphoma:
C 50202
- Intensive Chemotherapy and Immunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma
C 50303
- Phase III randomized study of R-CHOP vs. dose-adjusted EPOCH-R with molecular profiling in untreated DeNovo diffuse large B-cell lymphomas
C 50401
- A Randomized Phase II Trial of Rituximab vs. Lenalidomide (Revlimid™, CC-5013) (IND # 73034) vs. Rituximab + Lenalidomide in Recurrent Follicular Non-Hodgkin Lymphoma (NHL) After Relapse from a Rituximab-Containing Combination Regimen
Melanoma:
CTSU-E1697
- Phase III Randomized Study of Four Weeks High Dose
IFN-α2b in Stage T2b No, T3a-bN0, T4a-b No, and T1-4, N1a, 2a (microscopic) Melanoma
Neuropathy:
CALGB-170601
- A phase III double blind trial of oral Duloxetine for treatment of pain associated with chemotherapy induced peripheral neuropathy study (CIPN)
Other:
C 70604
A randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Pancreatic:
P EFC6596-PAPRIKA
- A Randomized, Open Label Multi-Center Study of Single Agent Larotaxel (XRP9881) Compared to Continuous Administration of 5-FU For The Treatment of Patients With Advanced Pancreatic Cancer Previously Treated With A Gemcitabine-Containing Regimen
Prostate:
CTSU E-3805
- CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease Prostate Cancer
CTSU R-0521
- A phase III protocol of androgen suppression (AS and 3DCRT/IMRT vs AS and 3DCRT/IMRT followed by chemotherapy with docetaxel and prednisone for localized, high-risk prostate cancer (only 3D CRT will be offered)
Renal:
CTSU E-2804
- The BeST Trial: A Randomized Phase II Study of VEGF, RAF kinase, and mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma
CTSU E-2805
- A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib vs Sorafenib vs Placebo in Patients with Resected Renal Cell Carcinoma
Prevention Trials: Select Participants Only
S 0000B
- Prevention of cataract and age-related macular degeneration with Vit.E and Selenium- (SEE), phase III ancillary to S-0000 SELECT
